324 related articles for article (PubMed ID: 31823199)
1. Cannabidiol Improves Cognitive Impairment and Reverses Cortical Transcriptional Changes Induced by Ketamine, in Schizophrenia-Like Model in Rats.
Kozela E; Krawczyk M; Kos T; Juknat A; Vogel Z; Popik P
Mol Neurobiol; 2020 Mar; 57(3):1733-1747. PubMed ID: 31823199
[TBL] [Abstract][Full Text] [Related]
2. Cannabidiol improves behavioural and neurochemical deficits in adult female offspring of the maternal immune activation (poly I:C) model of neurodevelopmental disorders.
Osborne AL; Solowij N; Babic I; Lum JS; Huang XF; Newell KA; Weston-Green K
Brain Behav Immun; 2019 Oct; 81():574-587. PubMed ID: 31326506
[TBL] [Abstract][Full Text] [Related]
3. Cannabidiol Modulates the Motor Profile and NMDA Receptor-related Alterations Induced by Ketamine.
Brakatselos C; Delis F; Asprogerakas MZ; Lekkas P; Tseti I; Tzimas PS; Petrakis EA; Halabalaki M; Skaltsounis LA; Antoniou K
Neuroscience; 2021 Feb; 454():105-115. PubMed ID: 32950556
[TBL] [Abstract][Full Text] [Related]
4. Effect of cannabidiol on endocannabinoid, glutamatergic and GABAergic signalling markers in male offspring of a maternal immune activation (poly I:C) model relevant to schizophrenia.
Osborne AL; Solowij N; Babic I; Lum JS; Newell KA; Huang XF; Weston-Green K
Prog Neuropsychopharmacol Biol Psychiatry; 2019 Dec; 95():109666. PubMed ID: 31202911
[TBL] [Abstract][Full Text] [Related]
5. Cannabidiol attenuates sensorimotor gating disruption and molecular changes induced by chronic antagonism of NMDA receptors in mice.
Gomes FV; Issy AC; Ferreira FR; Viveros MP; Del Bel EA; Guimarães FS
Int J Neuropsychopharmacol; 2014 Oct; 18(5):. PubMed ID: 25618402
[TBL] [Abstract][Full Text] [Related]
6. Cannabidiol attenuates behavioral changes in a rodent model of schizophrenia through 5-HT1A, but not CB1 and CB2 receptors.
Rodrigues da Silva N; Gomes FV; Sonego AB; Silva NRD; Guimarães FS
Pharmacol Res; 2020 Jun; 156():104749. PubMed ID: 32151683
[TBL] [Abstract][Full Text] [Related]
7. Effect of cannabidiol on muscarinic neurotransmission in the pre-frontal cortex and hippocampus of the poly I:C rat model of schizophrenia.
Jimenez Naranjo C; Osborne AL; Weston-Green K
Prog Neuropsychopharmacol Biol Psychiatry; 2019 Aug; 94():109640. PubMed ID: 31108177
[TBL] [Abstract][Full Text] [Related]
8. Alpha-lipoic acid alone and combined with clozapine reverses schizophrenia-like symptoms induced by ketamine in mice: Participation of antioxidant, nitrergic and neurotrophic mechanisms.
Vasconcelos GS; Ximenes NC; de Sousa CN; Oliveira Tde Q; Lima LL; de Lucena DF; Gama CS; Macêdo D; Vasconcelos SM
Schizophr Res; 2015 Jul; 165(2-3):163-70. PubMed ID: 25937462
[TBL] [Abstract][Full Text] [Related]
9. Peripubertal cannabidiol treatment rescues behavioral and neurochemical abnormalities in the MAM model of schizophrenia.
Stark T; Ruda-Kucerova J; Iannotti FA; D'Addario C; Di Marco R; Pekarik V; Drazanova E; Piscitelli F; Bari M; Babinska Z; Giurdanella G; Di Bartolomeo M; Salomone S; Sulcova A; Maccarrone M; Wotjak CT; Starcuk Z; Drago F; Mechoulam R; Di Marzo V; Micale V
Neuropharmacology; 2019 Mar; 146():212-221. PubMed ID: 30496751
[TBL] [Abstract][Full Text] [Related]
10. Decreased glial reactivity could be involved in the antipsychotic-like effect of cannabidiol.
Gomes FV; Llorente R; Del Bel EA; Viveros MP; López-Gallardo M; Guimarães FS
Schizophr Res; 2015 May; 164(1-3):155-63. PubMed ID: 25680767
[TBL] [Abstract][Full Text] [Related]
11. Sex-Specific Cannabidiol- and Iloperidone-Induced Neuronal Activity Changes in an In Vitro MAM Model System of Schizophrenia.
Thériault RK; St-Denis M; Hewitt T; Khokhar JY; Lalonde J; Perreault ML
Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34073710
[TBL] [Abstract][Full Text] [Related]
12. CBD Effects on Motor Profile and Neurobiological Indices Related to Glutamatergic Function Induced by Repeated Ketamine Pre-Administration.
Poulia N; Delis F; Brakatselos C; Ntoulas G; Asprogerakas MZ; Antoniou K
Front Pharmacol; 2021; 12():746935. PubMed ID: 34776964
[TBL] [Abstract][Full Text] [Related]
13. Cannabidiol prevents disruptions in sensorimotor gating induced by psychotomimetic drugs that last for 24-h with probable involvement of epigenetic changes in the ventral striatum.
Pedrazzi JFC; Sales AJ; Guimarães FS; Joca SRL; Crippa JAS; Del Bel E
Prog Neuropsychopharmacol Biol Psychiatry; 2021 Dec; 111():110352. PubMed ID: 34015384
[TBL] [Abstract][Full Text] [Related]
14. Involvement of GABAergic, BDNF and Nox-2 mechanisms in the prevention and reversal of ketamine-induced schizophrenia-like behavior by morin in mice.
Ben-Azu B; Aderibigbe AO; Ajayi AM; Eneni AO; Umukoro S; Iwalewa EO
Brain Res Bull; 2018 May; 139():292-306. PubMed ID: 29548911
[TBL] [Abstract][Full Text] [Related]
15. mGlu
Maksymetz J; Byun NE; Luessen DJ; Li B; Barry RL; Gore JC; Niswender CM; Lindsley CW; Joffe ME; Conn PJ
Cell Rep; 2021 Nov; 37(5):109950. PubMed ID: 34731619
[TBL] [Abstract][Full Text] [Related]
16. Morin Attenuates Neurochemical Changes and Increased Oxidative/Nitrergic Stress in Brains of Mice Exposed to Ketamine: Prevention and Reversal of Schizophrenia-Like Symptoms.
Ben-Azu B; Aderibigbe AO; Eneni AO; Ajayi AM; Umukoro S; Iwalewa EO
Neurochem Res; 2018 Sep; 43(9):1745-1755. PubMed ID: 29956036
[TBL] [Abstract][Full Text] [Related]
17. Altered dopamine D3 receptor gene expression in MAM model of schizophrenia is reversed by peripubertal cannabidiol treatment.
Stark T; Di Bartolomeo M; Di Marco R; Drazanova E; Platania CBM; Iannotti FA; Ruda-Kucerova J; D'Addario C; Kratka L; Pekarik V; Piscitelli F; Babinska Z; Fedotova J; Giurdanella G; Salomone S; Sulcova A; Bucolo C; Wotjak CT; Starcuk Z; Drago F; Mechoulam R; Di Marzo V; Micale V
Biochem Pharmacol; 2020 Jul; 177():114004. PubMed ID: 32360362
[TBL] [Abstract][Full Text] [Related]
18. Identification of Molecular Markers of Clozapine Action in Ketamine-Induced Cognitive Impairment: A GPCR Signaling PathwayFinder Study.
Korlatowicz A; Kuśmider M; Szlachta M; Pabian P; Solich J; Dziedzicka-Wasylewska M; Faron-Górecka A
Int J Mol Sci; 2021 Nov; 22(22):. PubMed ID: 34830086
[TBL] [Abstract][Full Text] [Related]
19. A systematic review of the antipsychotic properties of cannabidiol in humans.
Iseger TA; Bossong MG
Schizophr Res; 2015 Mar; 162(1-3):153-61. PubMed ID: 25667194
[TBL] [Abstract][Full Text] [Related]
20. Cannabidiol Counteracts Amphetamine-Induced Neuronal and Behavioral Sensitization of the Mesolimbic Dopamine Pathway through a Novel mTOR/p70S6 Kinase Signaling Pathway.
Renard J; Loureiro M; Rosen LG; Zunder J; de Oliveira C; Schmid S; Rushlow WJ; Laviolette SR
J Neurosci; 2016 May; 36(18):5160-9. PubMed ID: 27147666
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
